ImmuVen Inc., is a biotechnology company with novel technology to discover and develop new biotherapeutics to treat cancer, infectious disease, and autoimmune disorders. Based on proprietary technology developed in the laboratory of its scientific founder, ImmuVen’s platform allows rapid selection and optimization of T cell receptors with high affinity to targets in cancer, infections, and autoimmune pathways. ImmuVen has been supported through a combination of initial seed funding, federal grants, and collaborative work with pharmaceutical companies. ImmuVen’s value is driven by internal know-how, lead products for therapeutics and diagnostics, and intellectual property portfolio.
EnterpriseWorks Tenure: 2009-2013
After graduating from EnterpriseWorks in 2013, ImmuVen was acquired by AbbVie in 2014.